New drugs 2002, part 1.
D000577:Amides; D000636:Aminosalicylic Acids / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D000069580:Bimatoprost; D003008:Cloprostenol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003510:Cyclohexanes / Q000627:therapeutic use; D017277:Drug Approval; D004358:Drug Therapy / Q000451:nursing / Q000639:trends*; D064420:Drug-Related Side Effects and Adverse Reactions; D005702:Galantamine / Q000627:therapeutic use; D005901:Glaucoma / Q000188:drug therapy; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D008055:Lipids / Q000627:therapeutic use; D019804:Mesalamine; D000077715:Nateglinide; D018697:Nootropic Agents / Q000627:therapeutic use; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D010659:Phenylhydrazines; D010879:Piperazines / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use; D000069557:Travoprost
D000577:Amides; D000636:Aminosalicylic Acids; D000897:Anti-Ulcer Agents; D014150:Antipsychotic Agents; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D008055:Lipids; D018697:Nootropic Agents; D010659:Phenylhydrazines; D010879:Piperazines; D013844:Thiazoles; D005702:Galantamine; D000069036:Insulin Glargine; D007987:Gonadotropin-Releasing Hormone; D000077715:Nateglinide; D003008:Cloprostenol; D010649:Phenylalanine; D019804:Mesalamine; C092292:ziprasidone; C062876:cetrorelix; C038637:balsalazide; D000069580:Bimatoprost; D000069557:Travoprost